Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)

NCT04915755 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04915755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04915755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 28, 2021
Completion date
December 31, 2025
Enrollment
40 (actual)
Sites
198

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast